Abstract
Background: The steroidogenic acute regulatory protein (StAR) is essential for steroidogenesis by mediating cholesterol transfer into mitochondria. Inactivating StAR mutations cause lipoid congenital adrenal hyperplasia. Objective and Methods: To identify causative mutations in a patient presenting with adrenal failure during early infancy. The objective was to study the functional and structural consequences of the novel StAR mutation p.Trp147Arg in a Turkish patient detected in compound heterozygosity with the p.Glu169Lys mutation. Results: Transient in vitro expression of the mutant proteins together with P450 side-chain cleavage enzyme, adrenodoxin, and adrenodoxin reductase yielded severely diminished cholesterol conversion of the p.Trp147Arg mutant. The previously described p.Glu169Lys mutant led to significantly lower cholesterol conversion than wild-type StAR protein. As derived from three-dimensional protein modeling, the residue W147 is stabilizing the C-terminal helix in a closed conformation hereby acting as gatekeeper of the ligand cavity of StAR. Conclusions: The novel mutation p.Trp147Arg causes primary adrenal insufficiency and complete sex reversal in the 46,XY patient. Clinical disease, in vitro studies and three-dimensional protein modeling of the mutation p.Trp147Arg underscore the relevance of this highly conserved residue for StAR protein function.
References
1.
King SR, Bhangoo A, Stocco DM: Functional and physiological consequences of StAR deficiency: role in lipoid congenital adrenal hyperplasia. Endocr Dev 2011;20:47-53.
2.
Sandison AT: A form of lipoidosis of the adrenal cortex in an infant. Arch Dis Child 1955;30:538-541.
3.
Bose HS, Sugawara T, Strauss JF 3rd, Miller WL: The pathophysiology and genetics of congenital lipoid adrenal hyperplasia. N Engl J Med 1996;335:1870-1878.
4.
Bose HS, Pescovitz OH, Miller WL: Spontaneous feminization in a 46,XX female patient with congenital lipoid adrenal hyperplasia due to a homozygous frameshift mutation in the steroidogenic acute regulatory protein. J Clin Endocrinol Metab 1997;82:1511-1515.
5.
Fujieda K, Tajima T, Nakae J, Sageshima S, Tachibana K, Suwa S, Sugawara T, Strauss JF 3rd: Spontaneous puberty in 46,XX subjects with congenital lipoid adrenal hyperplasia. Ovarian steroidogenesis is spared to some extent despite inactivating mutations in the steroidogenic acute regulatory protein (STAR) gene. J Clin Invest 1997;99:1265-1271.
6.
Baker BY, Lin L, Kim CJ, Raza J, Smith CP, Miller WL, Achermann JC: Nonclassic congenital lipoid adrenal hyperplasia: a new disorder of the steroidogenic acute regulatory protein with very late presentation and normal male genitalia. J Clin Endocrinol Metab 2006;91:4781-4785.
7.
Metherell LA, Naville D, Halaby G, Begeot M, Huebner A, Nurnberg G, Nurnberg P, Green J, Tomlinson JW, Krone NP, Lin L, Racine M, Berney DM, Achermann JC, Arlt W, Clark AJ: Nonclassic lipoid congenital adrenal hyperplasia masquerading as familial glucocorticoid deficiency. J Clin Endocrinol Metab 2009;94:3865-3871.
8.
Lin D, Sugawara T, Strauss JF 3rd, Clark BJ, Stocco DM, Saenger P, Rogol A, Miller WL: Role of steroidogenic acute regulatory protein in adrenal and gonadal steroidogenesis. Science 1995;267:1828-1831.
9.
Stocco DM, Clark BJ: Role of the steroidogenic acute regulatory protein (STaR) in steroidogenesis. Biochem Pharmacol 1996;51:197-205.
10.
Tee MK, Lin D, Sugawara T, Holt JA, Guiguen Y, Buckingham B, Strauss JF 3rd, Miller WL: T→A transversion 11 bp from a splice acceptor site in the human gene for steroidogenic acute regulatory protein causes congenital lipoid adrenal hyperplasia. Hum Mol Genet 1995;4:2299-2305.
11.
Den Dunnen JT, Antonarakis SE: Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum Mutat 2000;15:7-12.
12.
Bens S, Mohn A, Yuksel B, Kulle AE, Michalek M, Chiarelli F, Nuri Ozbek M, Leuschner I, Grotzinger J, Holterhus PM, Riepe FG: Congenital lipoid adrenal hyperplasia: functional characterization of three novel mutations in the STAR gene. J Clin Endocrinol Metab 2010;95:1301-1308.
13.
Brentano ST, Miller WL: Regulation of human cytochrome P450scc and adrenodoxin messenger ribonucleic acids in JEG-3 cytotrophoblast cells. Endocrinology 1992;131:3010-3018.
14.
Brentano ST, Black SM, Lin D, Miller WL: Camp post-transcriptionally diminishes the abundance of adrenodoxin reductase MRNA. Proc Natl Acad Sci USA 1992;89:4099-4103.
15.
Thorsell AG, Lee WH, Persson C, Siponen MI, Nilsson M, Busam RD, Kotenyova T, Schuler H, Lehtio L: Comparative structural analysis of lipid binding START domains. PLoS One 2011;6:e19521.
16.
Murcia M, Faraldo-Gomez JD, Maxfield FR, Roux B: Modeling the structure of the START domains of MLN64 and STaR proteins in complex with cholesterol. J Lipid Res 2006;47:2614-2630.
17.
Kraulis PJ: Molscript: A program to produce both detailed and schematic plots of protein structures. J Appl Cryst 1991;24:946-950.
18.
Bhangoo A, Buyuk E, Oktay K, Ten S: Phenotypic features of 46,XX females with STaR protein mutations. Pediatr Endocrinol Rev 2007;5:633-641.
19.
Eiden-Plach A, Nguyen HH, Schneider U, Hartmann MF, Bernhardt R, Hannemann F, Wudy SA: Alu Sx repeat-induced homozygous deletion of the STAR gene causes lipoid congenital adrenal hyperplasia. J Steroid Biochem Mol Biol 2012;130:1-6.
20.
Fluck CE, Maret A, Mallet D, Portrat-Doyen S, Achermann JC, Leheup B, Theintz GE, Mullis PE, Morel Y: A novel mutation l260p of the steroidogenic acute regulatory protein gene in three unrelated patients of Swiss ancestry with congenital lipoid adrenal hyperplasia. J Clin Endocrinol Metab 2005;90:5304-5308.
21.
Fujieda K, Okuhara K, Abe S, Tajima T, Mukai T, Nakae J: Molecular pathogenesis of lipoid adrenal hyperplasia and adrenal hypoplasia congenita. J Steroid Biochem Mol Biol 2003;85:483-489.
22.
Gonzalez AA, Reyes ML, Carvajal CA, Tobar JA, Mosso LM, Baquedano P, Solar A, Venegas A, Fardella CE: Congenital lipoid adrenal hyperplasia caused by a novel splicing mutation in the gene for the steroidogenic acute regulatory protein. J Clin Endocrinol Metab 2004;89:946-951.
23.
Katsumata N, Tanae A, Shinagawa T, Nagashima-Miyokawa A, Shimizu M, Yasunaga T, Tanaka T, Hibi I: Homozygous Q258X mutation in the steroidogenic acute regulatory gene in a Japanese patient with congenital lipoid adrenal hyperplasia. Endocr J 1997;44:441-446.
24.
Nakae J, Tajima T, Sugawara T, Arakane F, Hanaki K, Hotsubo T, Igarashi N, Igarashi Y, Ishii T, Koda N, Kondo T, Kohno H, Nakagawa Y, Tachibana K, Takeshima Y, Tsubouchi K, Strauss JF 3rd, Fujieda K: Analysis of the steroidogenic acute regulatory protein (STaR) gene in Japanese patients with congenital lipoid adrenal hyperplasia. Hum Mol Genet 1997;6:571-576.
25.
Okuyama E, Nishi N, Onishi S, Itoh S, Ishii Y, Miyanaka H, Fujita K, Ichikawa Y: A novel splicing junction mutation in the gene for the steroidogenic acute regulatory protein causes congenital lipoid adrenal hyperplasia. J Clin Endocrinol Metab 1997;82:2337-2342.
26.
Ponting CP, Aravind L: START: a lipid-binding domain in StAR, HD-ZIP and signalling proteins. Trends Biochem Sci 1999;24:130-132.
27.
Soccio RE, Breslow JL: STaR-related lipid transfer (START) proteins: mediators of intracellular lipid metabolism. J Biol Chem 2003;278:22183-22186.
28.
Rodriguez-Agudo D, Ren S, Hylemon PB, Redford K, Natarajan R, Del Castillo A, Gil G, Pandak WM: Human STARD5, a cytosolic STaR-related lipid-binding protein. J Lipid Res 2005;46:1615-1623.
29.
Tsujishita Y, Hurley JH: Structure and lipid transport mechanism of a STaR-related domain. Nat Struct Biol 2000;7:408-414.
30.
Roostaee A, Barbar E, Lavigne P, LeHoux JG: The mechanism of specific binding of free cholesterol by the steroidogenic acute regulatory protein: evidence for a role of the C-terminal α-helix in the gating of the binding site. Biosci Rep 2009;29:89-101.
31.
Lavigne P, Najmanivich R, Lehoux JG: Mammalian STaR-related lipid transfer (START) domains with specificity for cholesterol: structural conservation and mechanism of reversible binding. Subcell Biochem 2010;51:425-437.
32.
Miller WL, Auchus RJ: The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr Rev 2011;32:81-151.
33.
Korsch E, Peter M, Hiort O, Sippell WG, Ure BM, Hauffa BP, Bergmann M: Gonadal histology with testicular carcinoma in situ in a 15-year-old 46,XY female patient with a premature termination in the steroidogenic acute regulatory protein causing congenital lipoid adrenal hyperplasia. J Clin Endocrinol Metab 1999;84:1628-1632.
34.
Savage MO, Lowe DG: Gonadal neoplasia and abnormal sexual differentiation. Clin Endocrinol 1990;32:519-533.
35.
Bhangoo A, Buyuk E, Oktay K, Ten S: Phenotypic features of 46, XX females with StAR protein mutations. Pediatr Endocrinol Rev 2007;5:633-641.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
